FDA Grants Priority Review to Fedratinib for Myelofibrosis

Based on the results from two clinical trials—the randomized, phase 3 JAKARTA trial and the single-arm, open-label phase 2 JAKARTA2 trial—the U.S. Food and Drug Administration granted priority review to the highly selective JAK2 inhibitor fedratinib for the treatment of myelofibrosis.